Full FDA Approval for Camptosar
ROCKVILLE, Md-The FDA has granted full approval to Pharmacia & Upjohn’s Camptosar (irinotecan), based on survival data. Camptosar is indicated for use in patients with metastatic colorectal cancer whose disease has recurred or spread after treatment with the current standard chemotherapy. The agent received accelerated FDA approval in June 1996.
ROCKVILLE, MdThe FDA has granted full approval to Pharmacia & Upjohns Camptosar (irinotecan), based on survival data. Camptosar is indicated for use in patients with metastatic colorectal cancer whose disease has recurred or spread after treatment with the current standard chemotherapy. The agent received accelerated FDA approval in June 1996.
Articles in this issue
Long-Term Adjuvant Tamoxifen Urged for Low-Risk Breast Cancer
EORTC DCIS Study Confirms Recurrence Reduction With RT
James Cancer Center Joins NCCN Outcomes Database
Managed Care Sees Need for National Guidelines, Accreditation
Advisory Panel Recommends Approval of Vysis HER2 Test
Drinking Tea After Smoking May Reduce Oxidative Stress
Roswell Park and Local HMO Use Claims Data to Study Regional Breast Cancer Care Patterns to Evaluate Quality
Use Special Skills, Tools to Assess Pain in Children, Elderly
Good Response Rates With Radiolabeled Anti-CD20 MoAB in NHL
Tobacco Industry Settles With States
Komen Foundation 1998 Awards Honor Leaders in Fight Against Breast Cancer
Dose Intensity, Density Increased in Breast Cancer
Full FDA Approval for Camptosar
CRFA Presents Frontlines Awards for Breast Cancer Awareness
Panel Recommends FDA Approval of DepoCyt
Recent Videos
